ÂÜÀòÂÒÂ×

Manal Morsy, MD, PhD, MBA, is a leading expert in global regulatory affairs, currently serving as Chief Regulatory Officer and Head of Global Regulatory Affairs at Vaxxinity since May 2024, focusing on innovative immunotherapy treatments for neurodegenerative disorders. Prior to Vaxxinity, Morsy held various senior positions at Athersys from 2013 to December 2023, overseeing regulatory strategies for regenerative therapies in critical medical needs. Morsy's extensive regulatory experience spans multiple companies, including PTC Therapeutics and Johnson & Johnson, and encompasses a broad array of therapeutic areas such as rare diseases, oncology, and infectious diseases. Morsy has contributed to numerous successful regulatory approvals worldwide, demonstrating a track record of expertise in navigating complex regulatory landscapes. Education includes an MD from Alexandria University, a PhD from Eastern Virginia Medical School, and an MBA from Drexel University.